SC Seeks Reports on Cheaper Cancer Drug Alternatives to Patented Medicines

Background: Cancer medications are among the most expensive healthcare commodities globally. India has a robust generic pharmaceutical industry capable of producing equivalent medicines at 60-80% lower cost. However, public hospitals often procure patented drugs due to supplier agreements, regulatory inertia, or perceived quality concerns. This drives up healthcare expenditure and limits access for economically disadvantaged patients.

Judicial reasoning: The HC recognized that substituting patented drugs with generic equivalents could redirect substantial public funds toward expanded treatment access without compromising therapeutic outcomes. The order invokes the right to health (Article 21) and constitutional obligation to provide healthcare.

Policy implications: If accepted, this could revolutionize drug procurement in government hospitals, benefiting millions of cancer patients. It challenges intellectual property norms while serving public health imperatives under the doctrine of proportionality.

Broad context: Aligns with India's National Pharmaceutical Pricing Authority (NPPA) framework and compulsory licensing provisions under Patent Act. Similar interventions have been seen in HIV/AIDS medications where generic alternatives transformed treatment accessibility.

Exam angle: Constitutional law (right to health, Article 21), intellectual property rights vs. public health, pharmaceutical pricing mechanisms, and healthcare policy. Questions on TRIPS flexibilities, compulsory licensing, and India's role in global healthcare. Relevant for UPSC GS-2 (Constitution), GS-3 (Healthcare), and law exams.